What's Happening?
Brii Biosciences has announced follow-up results from Cohort 4 of its Phase 2 ENSURE study, presented at the AASLD 2025. The study evaluates BRII-179, a therapeutic vaccine for chronic Hepatitis B, in combination
with elebsiran and pegylated interferon alfa (PEG-IFNα). The data show durable hepatitis B surface antigen (HBsAg) loss in BRII-179 anti-HBs responders, suggesting the potential to shorten PEG-IFNα treatment duration. The study aims to improve responsiveness to therapies offering a functional cure for HBV.
Why It's Important?
The results from Brii Biosciences' study highlight the potential of BRII-179 to enhance treatment outcomes for chronic Hepatitis B, a major global health challenge. The ability to achieve sustained HBsAg loss could lead to shorter treatment durations and improved patient outcomes. This development is crucial for addressing the high unmet medical needs in HBV treatment, particularly in regions with high infection rates like China.
What's Next?
Brii Biosciences is conducting additional Phase 2b trials to further define BRII-179's role in HBV treatment and optimize combination regimens. The ENRICH study evaluates BRII-179's ability to prime HBV-specific immunity, while the ENHANCE study explores various combination strategies. Both studies are fully enrolled, with end-of-treatment data expected in 2026. These trials aim to validate BRII-179's potential to deliver rapid and durable HBsAg loss.
